{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:12:05Z","timestamp":1790417525243,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00988","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T04:40:20Z","timestamp":1591936820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Ankit","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bineet","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra Kumar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/CMR.4.3.309","article-title":"Factors promoting acute and chronic diseases caused by yersiniae","volume":"4","author":"Brubaker","year":"1991","journal-title":"Clin Microbiol Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1128\/CMR.10.2.257","article-title":"Yersinia enterocolitica: the charisma continues","volume":"10","author":"Bottone","year":"1997","journal-title":"Clin Microbiol Rev."},{"key":"B3","first-page":"267","volume-title":"Plague","year":"2005"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-019-0105-9","article-title":"Plague vaccine: recent progress and prospects","volume":"4","author":"Sun","year":"2019","journal-title":"NPJ Vaccines."},{"key":"B5","doi-asserted-by":"publisher","first-page":"D56","DOI":"10.1016\/j.vaccine.2009.07.068","article-title":"Plague","volume":"27","author":"Williamson","year":"2009","journal-title":"Vaccine."},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/01.inf.0000106918.18570.dd","article-title":"Plague","volume":"23","author":"Dennis","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.tim.2015.11.008","article-title":"Pneumonic plague: the darker side of Yersinia pestis","volume":"24","author":"Pechous","year":"2016","journal-title":"Trends Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(07)60566-2","article-title":"Plague","volume":"369","author":"Prentice","year":"2007","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3389\/fimmu.2016.00602","article-title":"Plague vaccine development: current research and future trends","volume":"7","author":"Verma","year":"2016","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","article-title":"Plague as a biological weapon: medical and public health management. working group on civilian biodefense","volume":"283","author":"Inglesby","year":"2000","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6866","DOI":"10.1016\/j.vaccine.2011.07.059","article-title":"T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague","volume":"29","author":"Levy","year":"2011","journal-title":"Vaccine."},{"key":"B12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJM199709043371004","article-title":"Multi drug resistance in Yersinia pestis mediated by a transferable plasmid","volume":"337","author":"Galimand","year":"1997","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3201\/eid0701.010106","article-title":"Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis","volume":"7","author":"Guiyoule","year":"2001","journal-title":"Emerg Infect Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"13826","DOI":"10.1073\/pnas.0404012101","article-title":"Insights into the evolution of Yersinia pestis through whole-genome comparison with Yersinia pseudotuberculosis","volume":"101","author":"Chain","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1128\/JB.177.9.2530-2542.1995","article-title":"Differential effects of deletions in lcrV on secretion of V-antigen, regulation of the low-Ca++ response and virulence of Yersinia pestis","volume":"177","author":"Skrzypek","year":"1995","journal-title":"J Bacteriol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e3322","DOI":"10.1371\/journal.pntd.0003322","article-title":"HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model","volume":"8","author":"Batra","year":"2014","journal-title":"PLoS Neg Trop Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4172\/2155-9899.1000151","article-title":"Characterization of immune responses to Yersinia pestis (Indian isolate) infection in mouse model","volume":"4","author":"Verma","year":"2013","journal-title":"J Clin Cell Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"731604","DOI":"10.1155\/2012\/731604","article-title":"Advanced development of the rF1V and rBV A\/B vaccines: progress and challenges","volume":"2012","author":"Hart","year":"2012","journal-title":"Adv Prev Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1586\/erv.13.42","article-title":"Live-attenuated Yersinia pestis vaccines","volume":"12","author":"Wang","year":"2013","journal-title":"Expert Rev Vaccines."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1080\/21645515.2016.1175261","article-title":"Immunogenicity and safety of subunit plague vaccine: a randomized phase. 2 a clinical trial","volume":"12","author":"Chu","year":"2016","journal-title":"Hum Vaccine Immunother"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0264-410X(96)00303-9","article-title":"A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague","volume":"15","author":"Williamson","year":"1997","journal-title":"Vaccine."},{"key":"B22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.vaccine.2010.08.099","article-title":"TNF-\u03b1 and IFN-\u03b3 contribute to F1\/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague","volume":"29","author":"Lin","year":"2010","journal-title":"Vaccine."},{"key":"B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41541-018-0087-z","article-title":"Targeting of the Yersinia pestis F1 capsular antigen by innate like B1b cells mediates a rapid protective response against bubonic plague","volume":"3","author":"Levy","year":"2018","journal-title":"NPJ Vaccines."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3389\/fmicb.2016.01053","article-title":"A recombinant trivalent fusion protein F1-LcrV-HSP70(II) augments humoral and cellular immune responses and imparts full protection against Yersinia pestis","volume":"7","author":"Verma","year":"2016","journal-title":"Front Microbiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1091581813497405","article-title":"Preclinical safety assessment of a recombinant plague vaccine (rF1V)","volume":"32","author":"Price","year":"2013","journal-title":"Int J Toxicol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1586\/14760584.7.2.209","article-title":"Current challenges in the development of vaccines for pneumonic plague","volume":"7","author":"Smiley","year":"2008","journal-title":"Expert Rev Vaccines."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1016\/j.vaccine.2011.04.084","article-title":"Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague","volume":"29","author":"Williamson","year":"2011","journal-title":"Vaccine."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/j.vaccine.2009.02.016","article-title":"CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague","volume":"27","author":"Amemiya","year":"2009","journal-title":"Vaccine."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1128\/IAI.74.2.1113-1120.2006","article-title":"Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis","volume":"74","author":"Honko","year":"2006","journal-title":"Infect Immun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1016\/j.vaccine.2019.07.103","article-title":"Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague","volume":"37","author":"Bowen","year":"2019","journal-title":"Vaccine."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1086\/507644","article-title":"Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen","volume":"194","author":"Chiuchiolo","year":"2006","journal-title":"J Infect Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2147\/IJN.S56260","article-title":"Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague","volume":"9","author":"Huang","year":"2014","journal-title":"Int J Nanomed."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1128\/IAI.01860-05","article-title":"Immunogenicity protective immunity against bubonic plague pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV","volume":"74","author":"DeBord","year":"2006","journal-title":"Infect Immun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1016\/j.vaccine.2017.09.070","article-title":"A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin\/F1\/V, in healthy adult volunteers (DMID 08-0066)","volume":"35","author":"Frey","year":"2017","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.vaccine.2018.11.057","article-title":"Escherichia coli expressed flagellin C (FliC) of Salmonella Typhi improved the protective efficacy of YopE against plague infection","volume":"37","author":"Verma","year":"2019","journal-title":"Vaccine."},{"key":"B36","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4049\/jimmunol.156.2.873","article-title":"Adjuvant-free HSP70(II) fusion protein system elicits humoral and cellular responses to HIV-1 p24","volume":"156","author":"Suzue","year":"1996","journal-title":"J Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"13146","DOI":"10.1073\/pnas.94.24.13146","article-title":"Heat shock protein fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway","volume":"94","author":"Suzue","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"B38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1084\/jem.191.2.403","article-title":"In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4+ T cell independent","volume":"191","author":"Huang","year":"2000","journal-title":"J Exp Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1016\/S0264-410X(00)00492-8","article-title":"Heat shock proteins: the \u2018Swiss army knife' vaccines against cancers and infectious agents","volume":"19","author":"Srivastava","year":"2001","journal-title":"Vaccine."},{"key":"B40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0140-6736(03)14075-5","article-title":"Heat shock proteins as regulators of the immune response","volume":"362","author":"Pockley","year":"2003","journal-title":"Lancet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0145-305X(02)00160-X","article-title":"Evolution of heat shock protein and immunity","volume":"27","author":"Robert","year":"2003","journal-title":"Dev Comp Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1046-2023(03)00136-1","article-title":"Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting","volume":"31","author":"Hauser","year":"2003","journal-title":"Methods."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.4049\/jimmunol.169.5.2422","article-title":"Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein70","volume":"169","author":"Wang","year":"2002","journal-title":"J Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1083\/jcb.200205077","article-title":"Yersinia type III secretion send in the effectors","volume":"158","author":"Cornelis","year":"2002","journal-title":"J Cell Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1046\/j.1365-2958.1999.01408.x","article-title":"The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation","volume":"32","author":"Pettersson","year":"1999","journal-title":"Mol Microbiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1126\/science.1118476","article-title":"The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles","volume":"310","author":"Mueller","year":"2005","journal-title":"Science."},{"key":"B47","doi-asserted-by":"publisher","first-page":"16049","DOI":"10.1073\/pnas.0504728102","article-title":"A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence","volume":"102","author":"Sing","year":"2005","journal-title":"Proc Natl Acad Sci USA."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1128\/IAI.73.8.5152-5159.2005","article-title":"LcrV plague vaccine with altered immunomodulatory properties","volume":"73","author":"Overheim","year":"2005","journal-title":"Infect. Immun."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:21:34Z","timestamp":1696234894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2020.00988"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00988","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"article-number":"988"}}